USA Passive

iShares U.S. Pharmaceuticals ETF

The iShares U.S. Pharmaceuticals ETF (the “Fund”) seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector.

$62.73

+7.7% last 12 months

Compare similar ETFs

Fund Size
Dividend
Fees
Current
U.S. Pharmaceuticals ETF IHE
Fund Size
$652 Million
Dividend
1.4%
Fees
0.39%
Core S&P 500 ETF IVV
Fund Size
$402 Billion
Dividend
1.4%
Fees
0.03%
Core U.S. Aggregate Bond ETF AGG
Fund Size
$100 Billion
Dividend
3.3%
Fees
0.03%
FTSE All-World ex-US Index Fund VEU
Fund Size
$52.9 Billion
Dividend
3.4%
Fees
0.07%
S&P 500 Equal Weight ETF RSP
Fund Size
$51.3 Billion
Dividend
1.6%
Fees
-
View 365 similar ETFs →

Average metrics of all companies in portfolio

Compare to
Market
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $297 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 1.68 %
Beta Indicates the relationship between the price performance of a share and the market. 0.5859
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 67.95
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -54.04
Profitable Companies 83
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 489.13
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 9.43
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 22.14
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT 34.03
Enterprise Value to Revenue Enterprise value divided by revenue 11.02
Total Debt to Enterprise Value Total debt divided by enterprise value 0.16
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. -1.6301
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -44.76%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. -1.98%
Return on Assets Indicates a company's profitability in relation to its total assets. 9.39%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 15.95%

Industries

Healthcare 69.4%
Other 2.8%
N/A 27.8%

Market cap

Micro Cap 2%
Small Cap 7%
Mid Cap 22%
Large Cap 16%
Mega Cap 53%

36 Investments

P/E-Ratio
Total Investment
Weight
JOHNSON & JOHNSON logo

JNJ - Manufacturing

JOHNSON & JOHNSON

P/E-Ratio
10.0
Total Investment
$135 Million
Weight
21.5%
ELI LILLY AND COMPANY logo

LLY - Manufacturing

ELI LILLY AND COMPANY

P/E-Ratio
135.3
Total Investment
$134 Million
Weight
21.2%
VIATRIS INC. logo

VIATRIS INC.

P/E-Ratio
n/a
Total Investment
$30.3 Million
Weight
4.8%
ZOETIS INC. logo

ZTS - Manufacturing

ZOETIS INC.

P/E-Ratio
29.9
Total Investment
$29.4 Million
Weight
4.7%
MERCK & CO., INC. logo

MERCK & CO., INC.

P/E-Ratio
n/a
Total Investment
$27.9 Million
Weight
4.4%
BRISTOL-MYERS SQUIBB COMPANY logo

BMY - Manufacturing

BRISTOL-MYERS SQUIBB COMPANY

P/E-Ratio
12.4
Total Investment
$27.8 Million
Weight
4.4%
PFIZER INC. logo

PFIZER INC.

P/E-Ratio
n/a
Total Investment
$27 Million
Weight
4.3%
ROYALTY PHARMA PLC logo

RPRX - Manufacturing

ROYALTY PHARMA PLC

P/E-Ratio
11.0
Total Investment
$26.4 Million
Weight
4.2%
CATALENT, INC. logo

CATALENT, INC.

P/E-Ratio
n/a
Total Investment
$23.6 Million
Weight
3.8%
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY logo

JAZZ - Manufacturing

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

P/E-Ratio
16.6
Total Investment
$22.6 Million
Weight
3.6%
BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares logo

BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares

P/E-Ratio
n/a
Total Investment
$22.2 Million
Weight
3.5%
ELANCO ANIMAL HEALTH INCORPORATED logo

ELAN - Manufacturing

ELANCO ANIMAL HEALTH INCORPORATED

P/E-Ratio
-5.4
Total Investment
$21.4 Million
Weight
3.4%
Intra-Cellular Therapies Inc logo

ITCI - Manufacturing

Intra-Cellular Therapies Inc

P/E-Ratio
0.0
Total Investment
$18.7 Million
Weight
3.0%
PERRIGO COMPANY PUBLIC LIMITED COMPANY logo

PRGO - Manufacturing

PERRIGO COMPANY PUBLIC LIMITED COMPANY

P/E-Ratio
-319.5
Total Investment
$12.7 Million
Weight
2.0%
ORGANON & CO. logo

OGN - Manufacturing

ORGANON & CO.

P/E-Ratio
4.5
Total Investment
$10.8 Million
Weight
1.7%
AXSOME THERAPEUTICS, INC. logo

AXSM - Manufacturing

AXSOME THERAPEUTICS, INC.

P/E-Ratio
-13.0
Total Investment
$9.01 Million
Weight
1.4%
PRESTIGE CONSUMER HEALTHCARE INC. logo

PRESTIGE CONSUMER HEALTHCARE INC.

P/E-Ratio
n/a
Total Investment
$8.87 Million
Weight
1.4%
CORCEPT THERAPEUTICS INCORPORATED logo

CORT - Manufacturing

CORCEPT THERAPEUTICS INCORPORATED

P/E-Ratio
22.1
Total Investment
$8.56 Million
Weight
1.4%
CymaBay Therapeutics Inc logo

CBAY - Manufacturing

CymaBay Therapeutics Inc

P/E-Ratio
0.0
Total Investment
$7.43 Million
Weight
1.2%
AMPHASTAR PHARMACEUTICALS INC logo

AMPH - Manufacturing

AMPHASTAR PHARMACEUTICALS INC

P/E-Ratio
13.7
Total Investment
$6.75 Million
Weight
1.1%
Arvinas Inc logo

ARVN - Manufacturing

Arvinas Inc

P/E-Ratio
-6.4
Total Investment
$6.6 Million
Weight
1.0%
SUPERNUS PHARMACEUTICALS, INC. logo

SUPN - Manufacturing

SUPERNUS PHARMACEUTICALS, INC.

P/E-Ratio
1200.8
Total Investment
$4.62 Million
Weight
0.7%
PACIRA BIOSCIENCES, INC. logo

PCRX - Manufacturing

PACIRA BIOSCIENCES, INC.

P/E-Ratio
28.9
Total Investment
$4.58 Million
Weight
0.7%
LIGAND PHARMACEUTICALS INCORPORATED logo

LGND - Manufacturing

LIGAND PHARMACEUTICALS INCORPORATED

P/E-Ratio
24.6
Total Investment
$3.42 Million
Weight
0.5%
HARMONY BIOSCIENCES HOLDINGS, INC. logo

HARMONY BIOSCIENCES HOLDINGS, INC.

P/E-Ratio
n/a
Total Investment
$3.09 Million
Weight
0.5%